News Sentiment

XRTX sentiment intelligence

XORTX Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.01 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-7.6% over one week, -3.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

XORTX Therapeutics (XRTX) Investor presentation Summary

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -7.6% Price reacting lower
Trend fit Trend inactive -3.8% over four weeks
Fair value -76.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 34
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
TradingKey 6
dars.gov.et 5
Stock Titan 5
GlobeNewswire 5
TradingView 4
MT Newswires 4
Moomoo 3

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 15
Regulatory and legal 3
Guidance 2
Balance sheet 1
Capital return 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Quartr Direct company coverage

XORTX Therapeutics (XRTX) Investor presentation Summary

This article summarizes an investor presentation by XORTX Therapeutics (XRTX), highlighting its drug candidates XRx-026 for gout and XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). XRx-026 targets a significant market opportunity with NDA submission planned for

Tone
Neutral 50/100
Event
Market update
Published
20 Jul 2026 16:41
Source
Quartr
Quartr Direct company coverage

XORTX Therapeutics (XRTX) Q4 2024 earnings summary

XORTX Therapeutics (XRTX) reported an unqualified audit opinion for 2024, but with material uncertainty regarding its ability to continue as a going concern due to recurring operating losses and the need for additional financing. The company's cash decreased to $2.47M, and it rep

Tone
Negative 20/100
Event
Balance sheet
Published
20 Jul 2026 16:41
Source
Quartr
TradingView Direct company coverage

Price to earnings forward of XORTX Therapeutics, Inc. – LSX:A427MJ

This article focuses on the "Price to earnings forward" financial metric for XORTX Therapeutics, Inc. (A427MJ) listed on the Lang & Schwarz Exchange, according to TradingView. The content provided is minimal, indicating no trades and a closed market. It also highlights the origin

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 19:10
Source
TradingView
timothysykes.com Direct company coverage

XORTX Therapeutics Inc. (XRTX) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for XORTX Therapeutics Inc. (XRTX) stock. It shows the current stock price and highlights that there are no analyst ratings or earnings information currently available for the company. The page also includes general trading information an

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 10:39
Source
timothysykes.com
AD HOC NEWS Direct company coverage

Xortx Therapeutics updates investors on kidney disease focus

Xortx Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for progressive kidney disease and conditions associated with elevated uric acid. The company's strategy centers on long-term growth through clinical development milestones rather tha

Tone
Positive 63/100
Event
Market update
Published
07 Jul 2026 17:11
Source
AD HOC NEWS
TradingView Direct company coverage

Enterprise value to EBIT forward of XORTX Therapeutics, Inc. – TSXV:XRTX

This article focuses on the "Enterprise value to EBIT forward" metric for XORTX Therapeutics, Inc. (TSXV:XRTX). It is a financial data page from TradingView, displaying stock information for XORTX Therapeutics within the Health Technology and Pharmaceuticals sector on the TSX Ven

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 23:12
Source
TradingView
Moomoo Direct company coverage

XORTX Therapeutics(XRTX) Stock Options Chain | Quotes & News

This article provides access to the stock options chain, quotes, and news for XORTX Therapeutics (XRTX). It serves as a financial data portal for investors interested in the company's stock performance and related market activities.

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 21:41
Source
Moomoo
TradingView Direct company coverage

Price to sales forward of XORTX Therapeutics, Inc. – TSXV:XRTX

The article discusses the forward price-to-sales ratio for XORTX Therapeutics, Inc. (TSXV:XRTX). It also mentions that the stock market for XRTX is currently closed with no trades. The majority of the content consists of navigation links and policy information for the TradingView

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 04:10
Source
TradingView
TradingKey Direct company coverage

XORTX Therapeutics Inc (XRTX) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of XORTX Therapeutics Inc (XRTX) focusing on its financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. However, it notes that key financial data such as total revenue, operating profit, and

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 06:09
Source
TradingKey
TradingKey Direct company coverage

XORTX Therapeutics Inc (XRTX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for XORTX Therapeutics Inc (XRTX), detailing its current stock price, market cap, and daily performance. It notes that key valuation metrics such as P/E, P/B, P/S, and P/CF ratios have not been disclosed by the company yet. The content i

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 02:39
Source
TradingKey
TradingKey Direct company coverage

XORTX Therapeutics Inc (XRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

XORTX Therapeutics Inc (XRTX) has a "Buy" trend rating based on one analyst's assessment, with a target price of USD 14.00, representing a significant upside potential of +2943.48%. The article provides an overview of earnings forecasts, analyst ratings, and peer comparisons for

Tone
Positive 80/100
Event
Earnings
Published
18 Jun 2026 02:09
Source
TradingKey
TradingKey Direct company coverage

XORTX Therapeutics Inc (XRTX) Institutional Confidence

This article provides details on XORTX Therapeutics Inc (XRTX)'s institutional confidence, including its current stock price, market capitalization, and changes in institutional shareholdings. Several institutional investors and individuals are listed with their shareholdings and

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 02:09
Source
TradingKey
TradingKey Direct company coverage

XORTX Therapeutics Inc (XRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of XORTX Therapeutics Inc (XRTX) including its current stock price, market capitalization, and historical dividend and stock split information. It notes that the company has not distributed any dividends in the past five years but has undergone s

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 19:40
Source
TradingKey
TradingKey Direct company coverage

XORTX Therapeutics Inc (XRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides details on XORTX Therapeutics Inc (XRTX), including its market capitalization and recent stock performance. It notes that relevant revenue breakdown data by business segment and region has not yet been disclosed by the company. The page also serves as a gene

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 19:40
Source
TradingKey
Moomoo Direct company coverage

XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

This document is a 6-K report filed by XORTX Therapeutics, indicating it is a report of a foreign private issuer under the Securities Exchange Act. The content consists solely of the word "Document," suggesting it is a placeholder or a link to a separate document.

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 02:39
Source
Moomoo
Stock Titan Direct company coverage

A 28-year-old co-CEO and XORTX's $700M gout push in the US

XORTX Therapeutics has appointed Mika Grasso, 28, as co-CEO to oversee finance and public markets, coinciding with a corporate update detailing its strategic path for gout and kidney disease programs. The company is preparing an IND and planning a 505(b)(2) NDA submission for its

Tone
Positive 76/100
Event
Market update
Published
15 Jun 2026 10:40
Source
Stock Titan
Stock Titan Direct company coverage

XORTX Therapeutics (NASDAQ: XRTX) refocuses on gout program and appoints co-CEO

XORTX Therapeutics is strategically refocusing on its lead gout drug candidate, XRx-026, and expanding its leadership team with the appointment of Mika Grasso as co-CEO for finance and public markets. The company plans to submit an IND and an NDA via the 505(b)(2) pathway, suppor

Tone
Positive 71/100
Event
Market update
Published
15 Jun 2026 10:40
Source
Stock Titan
GlobeNewswire Direct company coverage

XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO

XORTX Therapeutics Inc. has provided a corporate update, refocusing on drug development programs and regulatory filings for its lead gout treatment, XRx-026. The company announced the appointment of Mika Grasso as Co-CEO, responsible for finance and public markets, and is advanci

Tone
Positive 75/100
Event
Regulatory and legal
Published
15 Jun 2026 07:00
Source
GlobeNewswire
The Globe and Mail Direct company coverage

XORTX to Voluntarily Delist from TSX Venture Exchange, Maintain Nasdaq Listing

XORTX Therapeutics Inc. (TSE:XRTX) announced its decision to voluntarily delist its common shares from the TSX Venture Exchange to reduce costs, administrative burdens, and regulatory complexities. The company will maintain its Nasdaq listing, ensuring all shareholders can contin

Tone
Negative 38/100
Event
Regulatory and legal
Published
14 Jun 2026 13:40
Source
The Globe and Mail
GlobeNewswire Direct company coverage

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

XORTX Therapeutics Inc. (NASDAQ: XRTX) has announced its decision to voluntarily delist its common shares from the TSX Venture Exchange to reduce costs, optimize financing initiatives, and minimize regulatory complexity. The company determined that maintaining a dual listing was

Tone
Neutral 50/100
Event
Regulatory and legal
Published
13 Jun 2026 12:10
Source
GlobeNewswire
Stock Titan Direct company coverage

XORTX Therapeutics (NASDAQ: XRTX) to voluntarily delist from TSX Venture

XORTX Therapeutics has announced its decision to voluntarily delist its common shares from the TSX Venture Exchange to reduce costs and administrative burdens associated with a dual listing. The company will maintain its listing on Nasdaq, where all shareholders will continue to

Tone
Positive 64/100
Event
Market update
Published
12 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

XORTX drops TSX Venture listing to reduce costs, focus on gout drug

XORTX Therapeutics Inc. (NASDAQ:XRTX) has voluntarily decided to delist its common shares from the TSX Venture Exchange to reduce costs and streamline operations, according to a strategic review. The move is expected to cut exchange, legal, and accounting fees, optimize financing

Tone
Neutral 50/100
Event
Deals and strategy
Published
12 Jun 2026 20:39
Source
Stock Titan
Finviz Direct company coverage

XRTX - XORTX Therapeutics Inc Stock Price and Quote

This article provides detailed stock information for XORTX Therapeutics Inc (XRTX), including its latest closing price, financial metrics, insider ownership, performance over various periods, and recent news releases. It covers aspects like market capitalization, sales, earnings

Tone
Neutral 50/100
Event
Earnings
Published
03 Jun 2026 20:40
Source
Finviz